Spero Therapeutics
SPRO
About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Employees: 32
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
195% more capital invested
Capital invested by funds: $10.9M [Q1] → $32.1M (+$21.3M) [Q2]
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
13% more funds holding
Funds holding: 38 [Q1] → 43 (+5) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
7.9% less ownership
Funds ownership: 27.71% [Q1] → 19.81% (-7.9%) [Q2]
68% less call options, than puts
Call options by funds: $447K | Put options by funds: $1.38M
Financial journalist opinion
